Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT108 in Unresectable or Metastatic Melanoma and Urinary Tract Tumors
NCT07280832Phase 2Recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
A Phase 2 trial of JMT108 in melanoma, urinary tract tumor, sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started Dec 2025; status: recruiting.
02
Drugs
JMT108
03
Conditions
melanomaurinary tract tumor
Beyond the preview
Go deeper on NCT07280832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280832.